- ESVONC
- Avenue Ceramique 222
- 6221 KX Maastricht
- The Netherlands
- Tel: +31(0)43 325 05 21
- office@esvonc.com
We will kick off with a precongress Resident Workshop on Wednesday 22 May.
For the main congress, again we will have 3 half-day Themed Sessions, where the next subjects will be discussed in-depth by experts in that field:
On Saturday 25 May ESVONC will organize the very first symposium for veterinary nurses and technicians: for the program, see on this link.
There will be 2 social events:
-----------------------------------------------------
This program is RACE approved: click to verify
Program Number: 36457, Provider Number: 1385, CE Hours:Vet: 11.50, Vet Tech: 4.25, Subject Matter Categories:Medical Program, Delivery Methods:Seminar/Lecture
| time | title | speaker |
| Radiation therapy and photodynamic therapy | ||
| 15:30-16:15 | Radiation biology – fundamental concepts for medical oncologists | dr. Carla Rohrer |
| 16:15-17:00 | Techniques in radiation therapy: 3DCRT, IMRT and beyond | dr. Carla Rohrer |
| 17:00-17:30 | Coffee break | |
| 17:30-18:15 | Brachytherapy and plesiotherapy in veterinary oncology | dr. Jérôme Benoit |
| 18:15-19:00 | Photodynamic therapy in veterinary oncology: principles and applications | dr. Julia Buchholz |
| time | title | speaker |
| 08h00-09h00 | Registration opens | |
| Themed session: Histiocytic proliferative diseases | ||
| 09:00-09:45 | Key note lecture: Current understanding of histiocytic proliferative diseases | dr. Jérôme Abadie, Nantes |
| 09:45-10:30 | Pathophysiological and genetic mechanisms associated with histiocytic malignancies | dr. Benoit Hédan, Nantes |
| 10:30-11:00 | coffee break | |
| 11:00-11:12 | Periarticular histiocytic sarcoma (PAHS) – Epidemiology, clinical characteristics and prognosis in 70 dogs | dr. Julia Gedon |
| 11:14-11:28 | Comparison of computed tomographic (CT) appearance of pulmonary involvement in localized and systemic histiocytic sarcoma in dogs | dr. Jan Wennemuth |
| 11:30-12:15 | Clinical management of canine systemic histiocytic sarcoma: past, present and what is up on the horizon? | dr. Jane Dobson, Cambridge |
| 12:15-12:45 | Round table discussion | all speakers |
| 12:45-13:00 | Welcome ESVONC to Frankfurt! – what to see and what to do! | dr. Martin Kessler |
| 13:00-14:15 | Lunch | |
| Resident abstracts | ||
| 14:15-14:27 | Adjuvant dose-intense versus metronomic chemotherapy for dogs with metastatic splenic hemangiosarcoma: a multi-institutional retrospective study | dr. Carmit Chalfon |
| 14:29-14:41 | Is radiation therapy a useful treatment option for meningoencephalomyelitis of unknown origin in dogs? | dr. Maximilian Körner |
| 14:43-14:55 | DNA double-strand breaks quantification in U87 cell-line exposed to 165Holmium, combined with ionizing radiation | dr. Pauline Denoeux |
| 14:55-15:07 | Low dose metronomic cyclophosphamide as adjuvant treatment in feline mammary carcinomas – A preliminary evaluation | dr. Gonçalo Petrucci |
| 15:10-15:40 | Coffee break | |
| General abstracts | ||
| 15:40-15:52 | Evaluation of a double deleted oncolytic Vaccinia virus encoding FCU1 protein in dogs diagnosed with malignant solid tumors | dr. Jérémy Béguin |
| 15:55-16:07 | Canine anal sac adenocarcinoma with lymph node metastases treated with anal sacculectomy and lymphadenectomy: is there a need for a new staging system? | dr. Jean-Benoit Tanis |
| 16:09-16:21 | Definitive radiation therapy for dogs with oral papillary squamous cell carcinoma. | dr. Francine van der Steen |
| 16:30-17:30 | ESVONC Annual General Meeting (ESVONC members) | |
| 19:00-21:00 | Welcome reception on the river Main – see Frankfurt’s skyline by night |
| time | title | speaker |
| Themed session: Inflammation and cancer | ||
| 9:00-9:45 | Inflammation in cancer initiation and maintenance | prof. David Argyle, Edinburgh |
| 9:45-10:30 | Inflammation in tumor progression and metastasis | prof. Florian Greten, Frankfurt |
| 10:30-11:00 | Coffee break | |
| 11:00-11:30 | The role of Cyclooxygenase-2 in cancer stem cell survival and repopulation during anticancer therapy | dr. Lisa Pang, Edinburgh |
| 11:30-12:00 | COX-2–independent anticarcinogenic effects of COX-Inhibitors | prof. Sabine Grösch, Frankfurt |
| 12:00-12:30 | The use of COX-2 inhibitors in treating cancer: what’s the evidence? | prof. David Argyle, Edinburgh |
| 12:30-13:00 | Panel discussion | |
| 13:00-14:15 | Poster session, and invited snack lunch in the industrial exhibition | |
| General abstracts | ||
| 14:15-14:27 | Expression of HIF-1 alpha and hypoxia-related markers correlate with prognosis in canine appendicular osteosarcoma | dr. Cecilia Gola |
| 14:29-14:41 | Non-Injection site soft tissue sarcoma in cats: Outcome following adjuvant radiotherapy | dr. Alenka Lavra Zajc |
| 14:43-14:55 | Using the dog’s definitive-intent radiotherapy protocol for sinonasal carcinomas in cats: a multicenter retrospective assessment | dr. Katerina Stiborova |
| 14:57-15:09 | High-Resolution Transcriptome Analysis of Feline Mammary Carcinomas and derived cell lines | dr. Joé-Luis Granados Soler |
| 15:20-15:50 | Coffee break | |
| 15:50-16:02 | Outcomes of canine subcutaneous mast cell tumours treated with adjunctive radiation therapy | dr. Begoña Pons Gil |
| 16:02-16:14 | Radiotherapy Outcomes in Dogs with Solitary Plasma Cell Tumors: 29 Cases | dr. Blaise Burke |
| 16:14-16:26 | Outcome of canine high-risk cutaneous mast cell tumours treated with adjuvant radiation therapy alone or combined with chemotherapy | dr. Onne-Marju Russak |
| 16:26-16:38 | Malignant melanoma of the nasal planum in cats - A report of 6 cases | dr. Amalia Reck |
| 16:38-16:50 | Discovery of chromosomal amplifications in canine oral melanoma as a new prognostic factor | dr. Anaïs Prouteau |
| 16:50-17:02 | Controlled, Randomized Study of Intratumoral Tigilanol Tiglate (EBC-46) for Treatment of Canine Mast Cell Tumors | dr. Johannes Chad |
| 19:30-??:?? | Gala Dinner in Gesellschaftshaus Palmengarten |
| time | title | speaker |
| 8:00-9:00 | Guided tour through Hofheim Veterinary Hospital (one of the largest private veterinary hospitals in Europe) | |
| Themed session: pathologist – clinician interaction | ||
| 9:15-10:00 | Key note lecture by chair: How do you get what you need? Problems and pitfalls in the pathologist – clinician interaction | prof. Marije Risselada, Purdue |
| 10:00-10:45 | Determining resection margins as a pathologist – clean but close or too close to be clean? | dr. Annika Herrmann, Bristol |
| 10:45-11:15 | Coffee break - visiting the poster exhibition | |
| 11:15-12:00 | On the cutting edge: a surgical oncologist’s perspective on resection margins | prof. Marije Risselada, Purdue |
| 12:00-12:30 | Mitotic index, Ki67 – preanalytic complications, analytic variations and clinical implications | Jérôme Abadie, Nantes |
| 12:30-13:00 | Panel discussion: Reporting resection margins, histologic grades and proliferation markers – implications for postop decision making | all speakers |
| 13:00-14:15 | Lunch on your own | |
| General abstracts | ||
| 14:15-14:27 | Clinicopathologic characteristics, postoperative outcome and prognostic factors in 61 dogs with primary pulmonary carcinomas | dr. Tanja Plavec |
| 14:27-14:39 | Lymphoma risk by clade and age of diagnosis as potential markers of genetic risk in dogs. | dr. Peter Bennett |
| 14:40-15:00 | Announcement presentations for World Veterinary Cancer Conference 2020 Tokyo & ESVONC 2020 Syracusa | |
| 15:01-15:13 | Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: a 5-year experience in two veterinary oncology centers | dr. Laura Marconato |
| 15:13-15:25 | Canine splenic masses: a systematic review of the literature for possible pre-surgical determinants of malignancy and creation of a new grading system | dr. Valerie J. Poirier |
| 15:25-15:37 | USP7 inhibitor as a novel drug candidate for canine lymphoma/leukemia treatment | dr. Aleksandra Pawlak |
| 15:37-15:49 | A novel aggressive T-cell lymphoma/leukemia in young dogs | dr. Paul Avery |
| 15:49-16:01 | Canine multicentric lymphoma (CML): towards a European consensus for diagnostic imaging ? | dr. Catherine Ibisch |
| 16:01-16:13 | Refining the double two-thirds rule: the importance of breed and clinical presentation to predict the diagnosis of canine splenic mass lesions in 288 dogs | dr. Owen Davies |
| 16:15-16:30 | Farewell ceremony |